CL2021002521A1 - Compuestos heteocíclicos y sus usos. - Google Patents
Compuestos heteocíclicos y sus usos.Info
- Publication number
- CL2021002521A1 CL2021002521A1 CL2021002521A CL2021002521A CL2021002521A1 CL 2021002521 A1 CL2021002521 A1 CL 2021002521A1 CL 2021002521 A CL2021002521 A CL 2021002521A CL 2021002521 A CL2021002521 A CL 2021002521A CL 2021002521 A1 CL2021002521 A1 CL 2021002521A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- heteocyclic
- find
- oncology
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos heterocíclicos como inhibidores de Wee1. Los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades y pueden encontrar un uso particular en oncología.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831665P | 2019-04-09 | 2019-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002521A1 true CL2021002521A1 (es) | 2022-04-29 |
Family
ID=72748693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002521A CL2021002521A1 (es) | 2019-04-09 | 2021-09-28 | Compuestos heteocíclicos y sus usos. |
Country Status (14)
Country | Link |
---|---|
US (2) | US11332473B2 (es) |
EP (1) | EP3952877A4 (es) |
JP (1) | JP2022526831A (es) |
KR (1) | KR20210150476A (es) |
CN (1) | CN113939296A (es) |
AU (1) | AU2020271837A1 (es) |
BR (1) | BR112021019703A2 (es) |
CA (1) | CA3136492A1 (es) |
CL (1) | CL2021002521A1 (es) |
EA (1) | EA202192746A1 (es) |
IL (1) | IL287026A (es) |
MX (1) | MX2021012418A (es) |
SG (1) | SG11202110615TA (es) |
WO (1) | WO2020210375A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CN117616029A (zh) * | 2021-07-05 | 2024-02-27 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
WO2023016417A1 (zh) * | 2021-08-11 | 2023-02-16 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
WO2023045942A1 (zh) * | 2021-09-22 | 2023-03-30 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE427310T1 (de) | 2002-01-18 | 2009-04-15 | Kyorin Seiyaku Kk | Kondensierte bicyclische pyrimidinderivate |
CA2525383C (en) | 2003-06-06 | 2012-03-06 | Arexis Ab | Use of heterocyclic compounds as scce inhibitors |
US7205296B2 (en) | 2004-09-29 | 2007-04-17 | Portola Pharmaceuticals, Inc. | Substituted 2H-1,3-benzoxazin-4(3H)-ones |
AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
RU2010101052A (ru) | 2007-06-15 | 2011-07-20 | Банью Фармасьютикал Ко., Лтд (Jp) | Производные бициклоанилина |
CA2703489A1 (en) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
AU2009325400A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
DK2477628T3 (en) | 2009-09-15 | 2014-11-24 | Merck Sharp & Dohme | Preparation of crystalline hemihydratformer of dihydropyrazolopyrimidinon |
US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
CN104271576A (zh) | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
EP3368538B1 (en) | 2015-11-01 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
GB201612095D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
KR102030886B1 (ko) | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR102534962B1 (ko) | 2016-11-16 | 2023-05-22 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물 |
WO2018133829A1 (zh) | 2017-01-23 | 2018-07-26 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2018171633A1 (zh) | 2017-03-23 | 2018-09-27 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
MX2019011506A (es) | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
WO2019011228A1 (zh) | 2017-07-10 | 2019-01-17 | 上海瑛派药业有限公司 | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 |
CA3071405A1 (en) * | 2017-08-01 | 2019-02-07 | Recurium Ip Holdings, Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs |
CN109422754A (zh) | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
WO2019074979A1 (en) * | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
WO2019074981A1 (en) | 2017-10-09 | 2019-04-18 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CN109810111B (zh) | 2017-11-20 | 2023-10-27 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
WO2019134539A1 (zh) | 2018-01-05 | 2019-07-11 | 四川科伦博泰生物医药股份有限公司 | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 |
US11479555B2 (en) | 2018-02-23 | 2022-10-25 | Newave Pharmaceutical Inc. | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase |
US20200405723A1 (en) | 2018-02-28 | 2020-12-31 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
CN117720541A (zh) * | 2018-03-09 | 2024-03-19 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
US20220168313A1 (en) | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
US20220162229A1 (en) | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
EP3952876A4 (en) | 2019-04-09 | 2023-04-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
EP3952875A4 (en) | 2019-04-09 | 2022-12-28 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
-
2020
- 2020-04-08 KR KR1020217036088A patent/KR20210150476A/ko unknown
- 2020-04-08 CN CN202080040846.1A patent/CN113939296A/zh active Pending
- 2020-04-08 SG SG11202110615TA patent/SG11202110615TA/en unknown
- 2020-04-08 WO PCT/US2020/027297 patent/WO2020210375A1/en unknown
- 2020-04-08 JP JP2021559854A patent/JP2022526831A/ja active Pending
- 2020-04-08 MX MX2021012418A patent/MX2021012418A/es unknown
- 2020-04-08 BR BR112021019703A patent/BR112021019703A2/pt not_active Application Discontinuation
- 2020-04-08 EA EA202192746A patent/EA202192746A1/ru unknown
- 2020-04-08 US US16/843,713 patent/US11332473B2/en active Active
- 2020-04-08 AU AU2020271837A patent/AU2020271837A1/en not_active Abandoned
- 2020-04-08 EP EP20787951.1A patent/EP3952877A4/en not_active Withdrawn
- 2020-04-08 CA CA3136492A patent/CA3136492A1/en active Pending
-
2021
- 2021-09-28 CL CL2021002521A patent/CL2021002521A1/es unknown
- 2021-10-06 IL IL287026A patent/IL287026A/en unknown
-
2022
- 2022-05-12 US US17/743,061 patent/US20230118115A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2022526831A (ja) | 2022-05-26 |
EA202192746A1 (ru) | 2021-12-29 |
US20200325142A1 (en) | 2020-10-15 |
CA3136492A1 (en) | 2020-10-15 |
EP3952877A4 (en) | 2022-12-14 |
IL287026A (en) | 2021-12-01 |
MX2021012418A (es) | 2021-11-12 |
EP3952877A1 (en) | 2022-02-16 |
US11332473B2 (en) | 2022-05-17 |
BR112021019703A2 (pt) | 2021-12-14 |
US20230118115A1 (en) | 2023-04-20 |
AU2020271837A1 (en) | 2021-11-18 |
SG11202110615TA (en) | 2021-10-28 |
KR20210150476A (ko) | 2021-12-10 |
WO2020210375A1 (en) | 2020-10-15 |
CN113939296A (zh) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001671A1 (es) | Inhibidores de sos1 | |
CL2021002521A1 (es) | Compuestos heteocíclicos y sus usos. | |
CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
CO2022008969A2 (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
DOP2017000152A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
UY37205A (es) | Inhibidores de bromodominios | |
CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
CO2021000049A2 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
CL2019001481A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. | |
UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
UY37559A (es) | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton | |
CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
ECSP21026485A (es) | Piridazinonas y sus métodos de uso |